SGHT vs. ANGO, RCEL, UTMD, LUNG, INO, ARAY, CERS, LYRA, GUTS, and PROF
Should you be buying Sight Sciences stock or one of its competitors? The main competitors of Sight Sciences include AngioDynamics (ANGO), AVITA Medical (RCEL), Utah Medical Products (UTMD), Pulmonx (LUNG), Inovio Pharmaceuticals (INO), Accuray (ARAY), Cerus (CERS), Lyra Therapeutics (LYRA), Fractyl Health (GUTS), and Profound Medical (PROF). These companies are all part of the "surgical & medical instruments" industry.
AngioDynamics (NASDAQ:ANGO) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.
AngioDynamics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.83, suggesting that its stock price is 183% more volatile than the S&P 500.
AngioDynamics received 346 more outperform votes than Sight Sciences when rated by MarketBeat users. Likewise, 60.67% of users gave AngioDynamics an outperform vote while only 33.33% of users gave Sight Sciences an outperform vote.
AngioDynamics has higher revenue and earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.
89.4% of AngioDynamics shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 5.1% of AngioDynamics shares are held by company insiders. Comparatively, 27.1% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
AngioDynamics has a net margin of -60.21% compared to AngioDynamics' net margin of -68.53%. Sight Sciences' return on equity of -3.48% beat AngioDynamics' return on equity.
AngioDynamics currently has a consensus price target of $14.25, suggesting a potential upside of 146.54%. Sight Sciences has a consensus price target of $4.60, suggesting a potential downside of 10.51%. Given Sight Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe AngioDynamics is more favorable than Sight Sciences.
In the previous week, Sight Sciences had 1 more articles in the media than AngioDynamics. MarketBeat recorded 2 mentions for Sight Sciences and 1 mentions for AngioDynamics. AngioDynamics' average media sentiment score of 0.22 beat Sight Sciences' score of 0.00 indicating that Sight Sciences is being referred to more favorably in the news media.
Summary
AngioDynamics beats Sight Sciences on 12 of the 18 factors compared between the two stocks.
Get Sight Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGHT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGHT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sight Sciences Competitors List
Related Companies and Tools
